Clinical Programs

News Releases

These are news releases that are related to our Investor efforts.  Releases are listed in chronological order and are archived by year.  Sign-up to receive news as it is released using the email and RSS tools below.

Advanced Search
  • Dec 22, 2015
    Rhodes Technologies, a Purdue Pharma group company, will supply Therapix with API for the R&D activity, in consideration for a future exclusive supply right and a right of negotiation to marketing the product in the U.S.

    Therapix Biosciences, a company engaged in the development of cannabinoid-based drugs, announces that it has signed an unbinding term-sheet with Rhodes Technologies, a Purdue Pharma group company,...

  • Dec 9, 2015
    Prof. Mechoulam, the “father of medical cannabis” is one of the industry’s pioneers, and was the first to describe the “entourage effect” which serves as basis for one of the Company’s technologies

    Therapix Biosciences announces the appointment of Prof. Raphael Mechoulam as member of the Company’s scientific advisory board, further to the decision to focus the Company’s business strategy...

  • Dec 9, 2015
    Dr. Elran Haber was appointed CEO of the Company and Doron Ben Ami was appointed VP Strategy of the Company

    Therapix, a company engaged in the development of drugs based on the active compounds in cannabis, announces today of key appointments to the Company’s management. Dr. Elran Haber was appointed...

  • Oct 26, 2015
    The investment agreements include a private placement to investors at NIS 1.05 per share, for a total of approx. NIS 3.3 million. In addition, the investors signed agreements for the exercise of options granted in the context of the Dekel transaction, for approx. NIS 2.3 million.

    Therapix, a company engaged in the development of cannabinoid-based drugs, announces today that it had entered into a series of investment agreements for a total of approx. NIS 5.6 million. The...

  • Aug 16, 2015

    The Company wishes to update, in respect of the Company’s investment agreement in LaraPharm Ltd., that further to discussions recently held between the Company and LaraPharm’s management, the...

Show 5102550100 per page